About Us - Optimax Access

Download your free ''HTA Process in the UK'' Guide

OPTImize Price, MAXimize Access

Optimax Access is a UK-based Health Economics and Outcome Research (HEOR) consultancy company based in the United Kingdom, with an office in the Netherlands as well. We assist our clients in introducing their pharmaceutical and biotech products, and services to major global healthcare markets. We will help you to identify a clear and optimal pathway to success with a comprehensive catalog of services ranging from clinical study design to reimbursement assessment, health economics evidence generation and health technology assessment dossier submission.

Optimax Access has been part of iGES Life Sciences Group (a 43-year-old company based in Germany with multiple offices in Europe) since 2019.

120

Models

100

Publications

HTA Submissions

200

Projects

What Make Us Special?

Lorem ipsum dolor sit amet, consectetur adipisc ing elit.

TEAM MEMBERS

A blend of experience from consultancy, industry and academia

Prof Dr Bertram Häussler

Chairman of the Board of Management

Bertram Häussler is head of the IGES group. He is an honorary professor at the Technical University of Berlin for Economics of the Pharmaceutical Industry. His scientific focus is on industrial economics, health economics, health care research, benefit assessment, and drug development.

Dr Amir Ansaripour

Associate Director

Amir is a pharmacist and health economist. He has collaborated with most of the top pharma companies by developing cost-effectiveness models for new products for various diseases. His Ph.D. research focused on cost-effectiveness analyses, modeling, and reimbursement policy analysis. During the past years, he has applied various methods such as questionnaire/survey analysis, Matching-adjusted indirect comparisons (MAICs), data mining on a large claims database, real-world cost analysis, Markov modeling, pharmaceutical pricing, and market access strategy in his projects.

Dr Mehdi Javanbakht

Chief Executive Officer

Mehdi holds a Ph.D. in Health Economics and has over 15+ years of experience in the Health Technology Assessment (HTA) field. He used to work as an Evidence Review Group (ERG) member for NICE. Mehdi has built over 120 health economic evaluation models from scratch for different diseases (Cancer, diabetes, cardiovascular diseases, Ophthalmology, …) and has published over 130 papers in peer-reviewed journals. He has a strong commercial sense and in-depth knowledge of modeling.

Atefeh Mashayekhi

Head of Evidence Synthesis Team

Atefeh is the head of the Evidence Synthesis team at Optimax Access, she worked as an Evidence Synthesis Analyst at NIHR Innovation Observatory for several years. She has a strong background in health economics and Evidence Synthesis and has successfully managed several systematic review projects as part of NICE HTA submissions for pharmaceutical and medical devices companies. She has also published several Cochrane systematic reviews.

Eoin Moloney

Senior Consultant

Eoin (MSc) is a senior health economist and evidence synthesis specialist, with 10 years of experience in academia and industry. He has worked across a wide range of clinical disease areas, focussing on the cost-effectiveness and budget-impact of a variety of medical and pharmaceutical interventions. He has a strong track record of publications in high-impact clinical and economic journals and an in-depth understanding of the methods required to demonstrate the cost-effectiveness of new technologies.

Melissa Gomez Montero

Senior Consultant

Melissa is a seasoned professional in Health Economics and Outcomes Research (HEOR), with extensive experience supporting pharmaceutical, biotech, and MedTech companies. She specializes in developing and adapting economic models, managing complex projects, and authoring scientific publications. Melissa holds an MSc in Health Economics from Erasmus University Rotterdam. After working at Cytel, she joined Optimax Access in May 2024, contributing to high-impact HEOR projects and publications. She is proficient in project management, statistical analysis, economic evaluation, and fluent in English, Spanish, French, and Portuguese.

Vasileios Kontogiannis

Consultant

Vasileios is a health economist with a BSc in Nutrition and Dietetics, an MSc in Public Health Practice, and an MSc in Economic Evaluation in Healthcare from the City University of London. He has experience in academia and industry and is interested in assessing the cost-effectiveness of health technologies using various modelling techniques. Vasilis has built and adapted cost-effectiveness and budget impact models for multiple countries and disease areas and has worked on Health Technology Assessment submissions.

Gamze Fackelmann

Marketing & Business Development Manager

Gamze is a marketing and business development expert with a strong background in pharmaceutical and medical industry. Holding a BSc in Molecular Biology and Genetics from ITU, an MBA with a marketing focus from ESSCA and ITU, and an MSc in Cancer Biology from UZH in Switzerland, Gamze combines scientific knowledge with business acumen. With a successful track record at renowned companies such as Pfizer and Novo Nordisk, she excels in formulating business development strategies, and executing marketing and sales campaigns.

Professor Maziar Moradi-Lakeh

Head of Clinical Research Team

Maziar is a Medical Doctor with post-graduate studies in health metric and evaluation. He has been a consultant for several international organizations, governments, and companies. Maziar has contributed to publishing more than 180 papers in peer-reviewed journals.